These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38363694)

  • 21. Familial hypercholesterolemia in children.
    Rodenburg J; Vissers MN; Wiegman A; Trip MD; Bakker HD; Kastelein JJ
    Curr Opin Lipidol; 2004 Aug; 15(4):405-11. PubMed ID: 15243213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease.
    Hedegaard BS; Bork CS; Kaltoft M; Klausen IC; Schmidt EB; Kamstrup PR; Langsted A; Nordestgaard BG
    J Am Coll Cardiol; 2022 Nov; 80(21):1998-2010. PubMed ID: 36396201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evinacumab for Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
    N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular Outcome of Pediatric Patients With Bi-Allelic (Homozygous) Familial Hypercholesterolemia Before and After Initiation of Multimodal Lipid Lowering Therapy Including Lipoprotein Apheresis.
    Taylan C; Driemeyer J; Schmitt CP; Pape L; Büscher R; Galiano M; König J; Schürfeld C; Spitthöver R; Versen A; Koziolek M; Marsen TA; Stein H; Schaefer JR; Heibges A; Klingel R; Oh J; Weber LT; Klaus G
    Am J Cardiol; 2020 Dec; 136():38-48. PubMed ID: 32946862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins for children with familial hypercholesterolemia.
    Vuorio A; Kuoppala J; Kovanen PT; Humphries SE; Strandberg T; Tonstad S; Gylling H
    Cochrane Database Syst Rev; 2010 Jul; (7):CD006401. PubMed ID: 20614444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P
    Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
    Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
    J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Lozano P; Henrikson NB; Dunn J; Morrison CC; Nguyen M; Blasi PR; Anderson ML; Whitlock EP
    JAMA; 2016 Aug; 316(6):645-55. PubMed ID: 27532919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis.
    Barkas F; Nomikos T; Liberopoulos E; Panagiotakos D
    Nutrients; 2020 Aug; 12(8):. PubMed ID: 32823643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
    Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry.
    Kayıkcioglu M; Başaran Ö; Doğan V; Mert KU; Mert GÖ; Özdemir İH; Rencüzoğulları İ; Karadeniz FÖ; Tekinalp M; Aşkın L; Demirelli S; Gencer E; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Cinier G; Akay KH; Pekel N; Utku Şenol ; Demir V; İnci S; Derviş E; Özlek B; Özlek E; Çelik O; Çil C; Biteker M
    J Clin Lipidol; 2023; 17(6):732-742. PubMed ID: 38072583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
    Kataoka Y; Funabashi S; Doi T; Harada-Shiba M
    J Atheroscler Thromb; 2022 Jun; 29(6):795-807. PubMed ID: 35022364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.
    Reijman MD; Tromp TR; Hutten BA; Hovingh GK; Blom DJ; Catapano AL; Cuchel M; Dann EJ; Gallo A; Hudgins LC; Raal FJ; Ray KK; Sadiq F; Soran H; Groothoff JW; Wiegman A; Kusters DM; ;
    Lancet Child Adolesc Health; 2024 Jul; 8(7):491-499. PubMed ID: 38759658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.